Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharmacyclics
Pharma
J&J, AbbVie's Imbruvica is first drug to treat kids with cGVHD
Johnson & Johnson and AbbVie’s Imbruvica has gained its first pediatric nod. This one is for chronic graft-versus-host disease.
Kevin Dunleavy
Aug 25, 2022 9:37am
AbbVie, Roche pad case for fixed-duration Venclexta use in CLL
Dec 8, 2019 11:16am
J&J, AbbVie shore up Imbruvica's CLL lead with Gazyva combo win
Jan 28, 2019 12:20pm
J&J, AbbVie star Imbruvica flunks pancreatic cancer test
Jan 21, 2019 9:43am
J&J, AbbVie tout Imbruvica data in the face of a new AZ threat
Dec 11, 2017 9:20am
